Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper

By Ben Comer, Chief Editor, Life Science Leader

Beginning in 2008 as a Gothenburg, Sweden-based spin-out of AstraZeneca, Albireo Pharma was created on the founders’ — Jan Mattsson and Per-Göran Gillberg — expertise in novel bile acid modulators. In 2015, Albireo established an office in Boston and hired Ron Cooper as president and CEO. One year later, Albireo became a publicly traded company through a share exchange and merger with Biodel Inc., a Danbury, CT-based specialty pharmaceutical company.